Research programme: mescaline derivatives - Enveric Biosciences
Alternative Names: EVM 401 series; EVM-401Latest Information Update: 02 Dec 2025
At a glance
- Originator MagicMed Industries
- Developer Enveric Biosciences
- Class Alkaloids; Antipsychotics; Neuropsychotherapeutics; Phenethylamines; Phenyl ethers
- Mechanism of Action Serotonin 5-HT2 receptor agonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Mental disorders; Neurological disorders
Most Recent Events
- 26 Nov 2025 Enveric Biosciences receives patent allowance for EVM 401 series of molecules in USA
- 14 Nov 2025 Enveric Biosciences has two patent protection for aminated psilocybin derivatives in the EVM 401 Series in USA
- 14 Nov 2025 Enveric Biosciences receives patent allowance for EVM 401 series of molecules in USA